This paper provides a rationale for conducting clinical trials to test the use of metformin, GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors in various non-diabetic kidney diseases. The gene discussed is SLC5A2; the disease is diabetic kidney disease.